人乳头瘤病毒基因型与宫颈上皮内瘤变2级主动监测女性持续/进展风险
该历史队列研究纳入2000至2010年在奥胡斯大学医院诊断为宫颈上皮内瘤变2级的23至40岁女性455例,采用HPV SPF10-DEIA-LiPA25系统对存档组织进行基因分型,评估HPV型别与持续/进展风险。结果显示HPV-16阳性者持续/进展风险显著高于非HPV-16者(相对风险1.64,95%CI 1.37-1.95),HPV-16阳性且基线细胞学高级别者风险最高(相对风险1.29,95%CI 1.03-1.61)。作者认为该组女性应考虑早期切除治疗。
要点
- HPV-16阳性女性持续/进展风险为非HPV-16者的1.64倍(95%CI 1.37-1.95)。
- HPV-16阳性且基线细胞学高级别者风险高于低级别者(相对风险1.29,95%CI 1.03-1.61)。
- 各年龄组间持续/进展风险无差异。
核心结论
- 持续/进展风险最高见于HPV-16阳性女性,尤其是合并高级别细胞学者。
- 作者认为该组女性应考虑早期切除治疗。
研究设计与样本
- 历史队列研究,纳入2000至2010年奥胡斯大学医院诊断为宫颈上皮内瘤变2级的23至40岁女性455例。
- 通过丹麦病理数据库(DPDB)识别,主动监测定义为索引诊断后2年内首次宫颈活检记录且此前无环形电切术。
- 采用HPV SPF10-DEIA-LiPA25系统对存档组织样本进行HPV基因分型。
- 持续/进展定义为随访期间活检或环形电切标本的最后且最差诊断为宫颈上皮内瘤变≥2级。
- 采用改良泊松模型估计相对风险(95%置信区间)。
主要发现
- 全部女性中52.2%在随访期间出现宫颈上皮内瘤变≥2级。
- 70.5%为HPV-16阳性,29.5%为其他HPV型别阳性。
- HPV-16阳性者持续/进展风险显著高于非HPV-16者(相对风险1.64,95%CI 1.37-1.95)。
- HPV-16阳性且基线细胞学高级别者持续/进展风险高于HPV-16阳性且细胞学低级别者(相对风险1.29,95%CI 1.03-1.61)。
- 各年龄组间未见差异。
临床怎么用
- 作者认为HPV-16阳性女性,尤其合并高级别细胞学者,应考虑早期切除治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, active surveillance has been introduced as an alternative to excisional treatment in younger women with cervical intraepithelial neoplasia grade 2 because regression rates are high and excisional treatment is associated with increased risk of preterm birth. However, early identification of women at increased risk of persistence/progression is important to ensure timely treatment. Evidence is limited on biomarkers that may be used to identify women at increased risk of persistence/progression. OBJECTIVE: This study aimed to describe human papillomavirus HPV type-specific persistence/progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2. STUDY DESIGN: We conducted a historical cohort study of women aged 23 to 40 years diagnosed with cervical intraepithelial neoplasia grade 2 at Aarhus University Hospital from 2000 to 2010. Women were identified through the Danish Pathology Data Bank (DPDB) and were considered as undergoing active surveillance if they had a first record of a cervical biopsy within 2 years after index diagnosis and no loop electrosurgical excision procedure before this. Human papillomavirus genotyping was performed on archived tissue samples using the HPV SPF10-DEIA-LiPA25 system (DNA ELISA [enzyme-linked immunosorbent assay] HPV SPF10 kit and RHA HPV SPF10-LiPA25 kit). Persistence/progression was defined as having a record of cervical intraepithelial neoplasia grade ≥2 in the DPDB determined on the last and worst diagnosis on a biopsy or loop electrosurgical excision procedure specimen during follow-up. We estimated the relative risk (95% confidence interval) of persistence/progression using a modified Poisson model. RESULTS: A total of 455 women were included. Two-thirds were aged ≤30 years (73.8%) at index diagnosis, and nearly half had a high-grade index cytology (48.8%). Overall, 52.2% of all women had cervical intraepithelial neoplasia grade ≥2 during follow-up; 70.5% were human papillomavirus-16-positive and 29.5% were positive for other human papillomavirus types. Human papillomavirus-16 was associated with a significantly higher risk of persistence/progression (relative risk, 1.64; 95% confidence interval, 1.37-1.95) compared with non-human papillomavirus-16. The risk of persistence/progression was highest in human papillomavirus-16-positive women with a high-grade index cytology compared with human papillomavirus-16-positive women with a low-grade cytology (relative risk, 1.29; 95% confidence interval, 1.03-1.61), whereas no differences were observed across age groups. CONCLUSION: The highest risk of persistence/progression was observed among human papillomavirus-16-positive women, particularly those with associated high-grade cytology. These findings suggest that early excisional treatment should be considered in this group of women.
引用
- Damgaard RK, Jenkins D, Stoler MH, et al. Human papillomavirus genotypes and risk of persistence and progression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2. Am J Obstet Gynecol. 2024. PMID: 38336125. doi:10.1016/j.ajog.2024.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。